TLSI — TriSalus Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $196.38m
- $215.08m
- $29.43m
Annual income statement for TriSalus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.43 | 8.4 | 12.4 | 18.5 | 29.4 |
| Cost of Revenue | |||||
| Gross Profit | 3.24 | 7.21 | 10.1 | 15.9 | 25.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 31.1 | 32.4 | 48.8 | 73 | 65.6 |
| Operating Profit | -25.6 | -24 | -36.4 | -54.5 | -36.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.8 | -28.8 | -47.2 | -59.4 | -30 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -31.8 | -28.8 | -47.2 | -59.4 | -30 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -31.8 | -28.8 | -47.2 | -59.4 | -30 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.8 | -28.8 | -50 | -63.6 | -33.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.21 | -1.1 | -1.9 | -6.77 | -1.31 |
| Dividends per Share |